FDA Recommends Reclassifying Marijuana as Less Restricted Drug

Regulations by 2FIRSTS.ai
Jan.15.2024
FDA Recommends Reclassifying Marijuana as Less Restricted Drug
FDA Supports Reclassifying Marijuana as a Less Restricted Substance, Citing Its Potential Medical Benefits

According to a report from the US media outlet Proceso on January 12th, the Food and Drug Administration (FDA) emphasized in a lengthy 250-page scientific review that marijuana has a lower potential for abuse compared to other similarly restricted drugs, highlighting its role in medical treatment.

 

According to reports, researchers at the FDA are said to support reclassifying marijuana from a Schedule I controlled substance to a Schedule III controlled substance. The rationale behind this is that marijuana has a lower potential for abuse compared to other drugs with similar restrictions. Additionally, there is scientific support for the medicinal uses of marijuana.

 

Currently, marijuana is classified as a Schedule I controlled substance in the United States, alongside substances such as heroin and LSD, making it one of the most dangerous substances. However, in 2022, US President Joe Biden has requested the Department of Health and Human Services (HHS) and the Attorney General to initiate an administrative review process to reconsider how such drugs are classified under federal law.

 

Federal scientists have concluded that marijuana does not possess a pronounced risk of abuse or addiction like other tightly regulated substances. Furthermore, they acknowledge the potential medical benefits of marijuana and therefore suggest removing it from the country's most strictly controlled drug category.

 

These recommendations were revealed in a comprehensive 250-page scientific review. The review was published online on Friday, January 12th, and its authenticity has been confirmed by an official from the Department of Health and Human Services (HHS).

 

According to the explanation in the documents, "these databases are consistent in terms of different substances and time, although the misuse of cannabis has clear harmful consequences, including substance use disorders, these cases are relatively rare and of lower severity.

 

According to the FDA's controlled substance personnel, they recommend reclassifying marijuana because it meets three criteria: it has a lower potential for abuse compared to schedule I and II substances, it is accepted for medical use in the United States, and it poses a low or moderate risk of physical dependence for those who abuse it. The National Institute on Drug Abuse supports these recommendations.

 

This information marks the first public disclosure of federal health officials' contemplation about making significant changes to marijuana at the federal level. While the concerned authorities have not openly commented on their discussions, marijuana has been classified as a Schedule I drug since 1970, alongside substances like heroin.

 

According to federal law, Schedule I drugs have no medical use and a high potential for abuse, with illegal use resulting in severe criminal penalties. Documents reveal that scientists from the FDA and National Institute on Drug Abuse suggest reclassifying marijuana as a Schedule III drug, akin to ketamine and testosterone which can be obtained through a doctor's prescription.

 

Conclusions drawn from the review conducted by federal scientists suggest that although marijuana is the most commonly abused illegal drug, "it produces fewer severe outcomes compared to Schedule I or II substances.

 

This examiner points out that the misuse of marijuana can potentially lead to physical dependence and, in certain cases, even psychological dependence, although the likelihood of severe consequences is minimal.

 

The evaluation also indicates that there is some "scientific support" for the therapeutic uses of marijuana, including treating conditions such as anorexia, pain, and chemotherapy-induced nausea and vomiting. It is worth noting that federal officials have cautioned that their analysis does not imply that they have conclusively determined marijuana to be safe and effective to support FDA approval. Their main objective is to emphasize that data supports some medical uses of marijuana.

 

Currently, the Drug Enforcement Administration (DEA) is considering this proposal and is expected to formally announce its decision in the coming months. The reclassification will undergo public comments and debates before the final decision is made.

 

According to federal statistics, marijuana is highly popular in the United States, with nearly 52 million people reported to have used it in 2021. Approximately 36 million individuals have reported using marijuana in the past month, placing it as the second most commonly used substance after alcohol and tobacco.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

New FDA Chief’s 100-Day Report: Cracking Down on Illegal E-Cigarettes, Advancing AI Tools for Oversight
New FDA Chief’s 100-Day Report: Cracking Down on Illegal E-Cigarettes, Advancing AI Tools for Oversight
U.S. FDA chief Marty Makary marked his first 100 days in office by outlining key reforms aimed at speeding drug approvals and tightening oversight. The agency unveiled a “national priority review” program to cut drug review times from 10–12 months to as little as 1–2 months, and partnered with customs to seize nearly $34 million in illegal e-cigarette products. The FDA also piloted its first AI-assisted review and launched “Elsa,” an internal generative AI tool to modernize regulatory processes.
Jul.11 by 2FIRSTS.ai
Philippines DTI Reports $740K in Illegal E-Cigarette Seizures and Removal of 100 Million Violation Records This Year
Philippines DTI Reports $740K in Illegal E-Cigarette Seizures and Removal of 100 Million Violation Records This Year
Between January and May 2025, the Philippine DTI seized $740,000 worth of illegal e-cigarettes from 88 unauthorized brands. Over 104 million online violations were removed, 628 businesses flagged, 385 legal notices issued, and 10 brands suspended.
May.28
Denssi's Global Strategy: Swedish Nicotine Pouch Brand Focuses on Flavor Innovation, Brand Storytelling in Africa and Middle East
Denssi's Global Strategy: Swedish Nicotine Pouch Brand Focuses on Flavor Innovation, Brand Storytelling in Africa and Middle East
Denssi COO Callum Cherry highlights that the brand stands out globally with “great flavors” and a unique story. Using differentiated strategies and sports sponsorships, Denssi builds a youthful, passionate image, focusing on emerging markets in Africa and the Middle East.
Jun.19 by 2FIRSTS.ai
Czech Republic Plans Ban on Candy-Flavored Vapes; Fruit and Mint Flavors Not Included
Czech Republic Plans Ban on Candy-Flavored Vapes; Fruit and Mint Flavors Not Included
The Czech Ministry of Health plans to revise regulations to ban sweet flavors like marshmallow in e-cigarettes while allowing tobacco and fruit flavors to remain. The move aims to reduce the appeal of such products to teenagers. Although current laws prohibit sales to minors, more than half of teens report easy access. The new rules will also tighten restrictions on cigarette packaging designs.
Jul.08 by 2FIRSTS.ai
EU Plans to Include Tobacco Tax in Long-Term Budget Revenue, Sparking Potential Member State Opposition
EU Plans to Include Tobacco Tax in Long-Term Budget Revenue, Sparking Potential Member State Opposition
The European Commission is considering making tobacco taxes a new revenue source for the next long-term EU budget, according to a German government document. The proposal, still at an exploratory stage, could face opposition from the tobacco industry and requires unanimous approval from member states.
Jul.10 by 2FIRSTS.ai
Russia to Include E-Cigarettes in Mandatory Labeling Pilot from July 14, Managed via the “Honest Sign” System
Russia to Include E-Cigarettes in Mandatory Labeling Pilot from July 14, Managed via the “Honest Sign” System
The Russian government is expanding its product labeling pilot to include e-cigarettes, adding them to the list of goods requiring labels. The pilot will run from July 14, 2025, to February 28, 2026, allowing market participants to voluntarily apply free QR codes to products that meet specific codes.
Jul.11 by 2FIRSTS.ai